Production (Stage)
Citius Oncology, Inc.
CTOR
$1.41
-$0.06-4.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.33M | 5.13M | 5.37M | 3.50M | 3.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.47M | 6.40M | 6.67M | 4.63M | 4.69M |
| Operating Income | -7.47M | -6.40M | -6.67M | -4.63M | -4.69M |
| Income Before Tax | -7.47M | -6.40M | -6.67M | -4.63M | -4.69M |
| Income Tax Expenses | 264.20K | 264.20K | 144.00K | 144.00K | 144.00K |
| Earnings from Continuing Operations | -7.74M | -6.66M | -6.81M | -4.77M | -4.84M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.74M | -6.66M | -6.81M | -4.77M | -4.84M |
| EBIT | -7.47M | -6.40M | -6.67M | -4.63M | -4.69M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.11 | -0.09 | -0.10 | -0.07 | -0.07 |
| Normalized Basic EPS | -0.07 | -0.06 | -0.06 | -0.04 | -0.04 |
| EPS Diluted | -0.11 | -0.09 | -0.10 | -0.07 | -0.07 |
| Normalized Diluted EPS | -0.07 | -0.06 | -0.06 | -0.04 | -0.04 |
| Average Basic Shares Outstanding | 71.55M | 71.55M | 69.71M | 67.50M | 67.50M |
| Average Diluted Shares Outstanding | 71.55M | 71.55M | 69.71M | 67.50M | 67.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |